Close Menu

NEW YORK (GenomeWeb) – Natera and Swiss biotech Amal Therapeutics plan to partner on a clinical trial to test Natera's bespoke circulating tumor DNA assay, Signatera, to assess treatment response in late-stage colorectal cancer patients.

The prospective clinical trial will assess Amal's cancer vaccine, ATP128, in combination with a PD-1 inhibitor in patients with stage IV colorectal cancer. Study investigators will use Signatera to measure patients' treatment response.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.